Nuvalent, Inc.
One Broadway, 14th Floor
Cambridge, Massachusetts 02142
August 12, 2022
VIA EDGAR SUBMISSION
U.S. Securities and Exchange Commission
Division of Corporation Finance, Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention: Daniel Crawford
| Re: | Nuvalent, Inc. |
Registration Statement on Form S-3
Filed August 10, 2022
File No. 333-266731
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Nuvalent, Inc. (the “Company”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-266731), so that it may become effective at 4:15 p.m., Eastern time, on August 16, 2022, or as soon as practicable thereafter.
Very truly yours, | ||
NUVALENT, INC. | ||
By: | /s/ James R. Porter, Ph.D. | |
Name: James R. Porter, Ph.D. | ||
Title: President and Chief Executive Officer | ||
